Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate leaves FTC provision off finance reform

This article was originally published in The Tan Sheet

Executive Summary

A congressional conference committee will decide whether to include a provision in financial services reform legislation provision that dramatically expands the Federal Trade Commission's rulemaking authority. The Senate passed a version of the Wall Street Reform and Consumer Protection Act, H.R. 4173, without a provision the House included that amends the FTC Act by removing procedural requirements from the commission's rulemaking and enforcement capabilities (1"The Tan Sheet" April 26, 2010). Dietary supplement industry trade groups and other industry organizations lobbied against the provision that would enable FTC to adopt trade regulations using the Administrative Procedure Act rulemaking procedure and no longer require the agency to obtain congressional approval before undertaking formal rulemaking procedures. The House and Senate will appoint conference committee members to negotiate a final bill that resolves differences over the FTC provision and other sections of the extensive legislation

You may also be interested in...



FTC Provision In Finance Reform Bill Could Bite Supplement Firms

Dietary supplement trade groups join a wide swath of industries telling Congress a minor provision of extensive financial services reform legislation would give the Federal Trade Commission nearly unfettered rulemaking authority

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel